Clinical TrialHeadache Disorders (Cluster & Migraine)LSDPlaceboRecruiting

LSD to Improve Cluster Headache Impact Trial

This double-blind, placebo-controlled trial (n=65) will assess the efficacy and safety of LSD (25μg) every 3 days for 3 weeks versus placebo in treating chronic cluster headaches (CCH).

Ask Blossom about this trial
Target Enrollment
65 participants
Study Type
Phase II interventional
Design
Randomized, quadruple Blind

Detailed Description

Randomized, double-blind, parallel-group Phase 2 trial comparing low‑dose LSD tartrate (25 µg per vial) given one dose every 3 days for 3 weeks (7 doses) versus matching placebo in adults with chronic cluster headache.

Design includes a 4‑week baseline observation period, 3‑week treatment period and 5‑week post‑treatment observation to assess acute and sustained effects; primary outcome is reduction in attack frequency at end of treatment.

Secondary objectives include safety, exposure–response exploration and cost‑effectiveness; background rationale arises from limited uncontrolled evidence suggesting low‑dose LSD may reduce attack frequency in refractory chronic cluster headache.

Study Protocol

Preparation

sessions

Dosing

7 sessions

Integration

sessions

Study Arms & Interventions

LSD 25µg

experimental

LSD tartrate equivalent to 25 µg LSD base; one dose every 3 days for 3 weeks (7 doses).

Interventions

  • LSD25 µg
    via Oral• one dose every 3 days• 7 doses total

    25 µg LSD base per vial

Placebo

inactive

Placebo vial matched to verum; one vial every 3 days for 3 weeks (7 doses).

Interventions

  • Placebo
    via Oral• one dose every 3 days• 7 doses total

    Matching placebo vial

Participants

Ages
16 – 75
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • CCH according to the International Classification of Headache Disorders version 3 (ICHD-3)
  • At screening: stable weekly attack frequency in the 4 weeks prior to screening (assessed retrospectively), averaging at least 8 per week and each week within a 40% window around the average
  • At randomization: average of at least 8 attacks per week and no absence of attacks on more than two consecutive days during baseline

Exclusion Criteria

  • Exclusion Criteria:
  • Use of excluded concomitant treatment at screening (lithium; other prophylactics if not on a stable dose for less than one month; steroids/GON block within 2 months before screening; sphenopalatinum block, neurostimulation (changed setting within 3 months before screening) or botulinum toxin within 3 months before screening) and during the double-blind phase
  • Use of LSD(-derivatives) (other than investigational drug), psilocybin, ketamine or cannabis within 3 months prior to screening and throughout the study
  • Lifetime and/or family history (first degree relatives) of psychotic or bipolar disorder, suicidal intention or attempt
  • A score of 6 or more on the 'Ervaringenlijst' (PQ-16) to exclude subclinical susceptibility to psychosis
  • Actual abuse of alcohol and/or recreational drugs
  • Lifetime history of cardiac valvular disease
  • History or evidence of cognitive disorder at screening
  • Positive urine drug screen at screening
  • Females: Pregnancy, lactation, no acceptable contraceptive use

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

Study Team

Locations

Leiden University Medical Center (LUMC) — Leiden, Netherlands
Canisius-Wilhelmina Ziekenhuis (CWZ) — Nijmegen, Netherlands

Your Personal Research Library

Go Pro to save trials, add notes, rate research, and organize custom shelves.

See Pro Plans